Vogenx taps board member Richard Gorman as Chief Commercial Officer, effective Oct 12
Vogenx, Inc.
Richard Gorman, an independent Vogenx director since 2022, becomes Chief Commercial Officer effective October 12, 2026, a newly created role.
Gorman resigned from the Board and its Audit, Compensation and Nominating/Corporate Governance committees effective Oct 12; no disagreement with the company cited.
He will lead commercial operations and corporate strategy, including market development for post-bariatric hypoglycemia and gastroparesis, plus business development and licensing.
Vogenx will search for a new independent director to fill the board seat; CEO James Green credited Gorman with shaping strategy through the August 2026 IPO.
Company says the hire supports advancing mizagliflozin into later-stage development; Gorman has 30 years of biopharma commercial experience.
Richard Gorman resigned from the Board of Directors
(“Board”) of the Company and from all committees of the Board on which he served, including the Audit Committee, the Compensation
Committee, and the Nominating and Corporate Governance Committee, effective October 12, 2026.
concurrent with his becoming
an employee of Vogenx, Inc. (the “Company”) as Chief Commercial Officer
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Richard Gorman resigned as Director at Vogenx, Inc..
Action
resigned
Role
Director
Exact text from the filing
Richard Gorman resigned from the Board of Directors (“Board”) of the Company and from all committees of the Board on which he served, including the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, effective October 12, 2026.
This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.